Limits...
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.

Lafeuillade A, Soriano V, Suzan-Monti M, Stevenson M, Izopet J, Stellbrink HJ - AIDS Res Ther (2012)

Bottom Line: However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted.Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual.The main 2012 ISHEID theme was, hence "searching for an HIV cure".

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Infectious Diseases, General Hospital, Toulon, France. alain.lafeuillade@ch-toulon.fr.

ABSTRACT
The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for investigators to hear the latest research developments in the clinical management of HIV and HCV infections as well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence "searching for an HIV cure". In this report we not only give details on this main topic of the 2012 ISHEID but also summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy management and recent progress in the therapy of HCV infection in patients with HIV.

No MeSH data available.


Related in: MedlinePlus

Different targets and drugs to reactivate proviral HIV-1 DNA from latency.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3472320&req=5

Figure 1: Different targets and drugs to reactivate proviral HIV-1 DNA from latency.

Mentions: Several approaches can be used to reactivate viral latency with the expectation that new cell infections can be blocked in vivo by immune surveillance or antiretroviral drugs. IL7 or PKC agonists like prostratin can induce cellular transcription factors (STAT 5, NF-KB). HDACi (Histone deacyltransferase inhibitors) like SAHA (Vorinostat) promote histone acetylation, HMTi (Histone methyltransferase inhibitors) like chaetocin decrease histone methylation and DNA methylation inhibitors like decitabine decrease DNA methylation. HMBA induce the recruitment of the kinase complex P-TEFb (Cyclin T1/CDK9) to the HIV-1 promoter. Synergistic activation of HIV-1 expression by prostratin and vorinostat has been observed in vitro. Similarly, synergistic activation of HIV-1 expression by prostratin and HMBA has been obtained. Therefore one of the most promising strategies to target latent reservoirs could reside in combinations of several families of compounds (Figure1).


Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.

Lafeuillade A, Soriano V, Suzan-Monti M, Stevenson M, Izopet J, Stellbrink HJ - AIDS Res Ther (2012)

Different targets and drugs to reactivate proviral HIV-1 DNA from latency.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3472320&req=5

Figure 1: Different targets and drugs to reactivate proviral HIV-1 DNA from latency.
Mentions: Several approaches can be used to reactivate viral latency with the expectation that new cell infections can be blocked in vivo by immune surveillance or antiretroviral drugs. IL7 or PKC agonists like prostratin can induce cellular transcription factors (STAT 5, NF-KB). HDACi (Histone deacyltransferase inhibitors) like SAHA (Vorinostat) promote histone acetylation, HMTi (Histone methyltransferase inhibitors) like chaetocin decrease histone methylation and DNA methylation inhibitors like decitabine decrease DNA methylation. HMBA induce the recruitment of the kinase complex P-TEFb (Cyclin T1/CDK9) to the HIV-1 promoter. Synergistic activation of HIV-1 expression by prostratin and vorinostat has been observed in vitro. Similarly, synergistic activation of HIV-1 expression by prostratin and HMBA has been obtained. Therefore one of the most promising strategies to target latent reservoirs could reside in combinations of several families of compounds (Figure1).

Bottom Line: However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted.Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual.The main 2012 ISHEID theme was, hence "searching for an HIV cure".

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Infectious Diseases, General Hospital, Toulon, France. alain.lafeuillade@ch-toulon.fr.

ABSTRACT
The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for investigators to hear the latest research developments in the clinical management of HIV and HCV infections as well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence "searching for an HIV cure". In this report we not only give details on this main topic of the 2012 ISHEID but also summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy management and recent progress in the therapy of HCV infection in patients with HIV.

No MeSH data available.


Related in: MedlinePlus